Duality Biotherapeutics (FRA:4ZB) EV-to-EBIT: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4ZB Duality Biotherapeutics Inc FRA:4ZB
19 GF Score
Price €19.70
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Duality Biotherapeutics's Enterprise Value is €1,459.3 Mil. Duality Biotherapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jun. 2026. Therefore, GuruFocus does not calculate Duality Biotherapeutics's EV-to-EBIT at this moment.

The historical rank and industry rank for Duality Biotherapeutics's EV-to-EBIT or its related term are showing as below:

FRA:4ZB' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.24   Med: -10.27   Max: -2.46
Current: -8.13

During the past 4 years, the highest EV-to-EBIT of Duality Biotherapeutics was -2.46. The lowest was -33.24. And the median was -10.27.

FRA:4ZB's EV-to-EBIT is ranked worse than
100% of 369 companies
in the Biotechnology industry
Industry Median: 14.64 vs FRA:4ZB: -8.13

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Duality Biotherapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was €1,472.6 Mil. Duality Biotherapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jun. 2026. Therefore, GuruFocus does not calculate Duality Biotherapeutics's Earnings Yield (Joel Greenblatt) % at this moment.

Duality Biotherapeutics  (FRA:4ZB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Duality Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2026 ) =EBIT / Enterprise Value (Q: Jun. 2026 )
=/1472.6451585249
= %

Duality Biotherapeutics EV-to-EBIT Related Terms

Duality Biotherapeutics EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics EV-to-EBIT Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EV-to-EBIT
0.00 0.00 0.00 -5.41

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
EV-to-EBIT 0.00 -7.77 -8.32

FRA:4ZB vs VRTX, REGN, MRNA: EV-to-EBIT Comparison

For the Biotechnology subindustry, Duality Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Duality Biotherapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Duality Biotherapeutics's EV-to-EBIT falls into.


FRA:4ZB
19GF Score
Duality Biotherapeutics Inc FRA:4ZB
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics EV-to-EBIT Calculation

Duality Biotherapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1459.326/
=

Duality Biotherapeutics Business Description

Other Exchanges 09606:Hong Kong
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score

Get the complete analysis for FRA:4ZB

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.70
Price